| scholarly article | Q13442814 |
| P50 | author | Simone Fulda | Q21264686 |
| Lisa Kowald | Q125350544 | ||
| P2093 | author name string | Sjoerd J L van Wijk | |
| Stefanie Rösler | |||
| Barbara Schenk | |||
| Anne-Kathrin Knuth | |||
| P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
| IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis | Q24300707 | ||
| Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis | Q24311815 | ||
| Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method | Q25938999 | ||
| Mechanisms of type-I- and type-II-interferon-mediated signalling | Q28247893 | ||
| Type I interferon induces necroptosis in macrophages during infection with Salmonella enterica serovar Typhimurium | Q28508897 | ||
| Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays | Q28646554 | ||
| Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death | Q28660873 | ||
| RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3 | Q33798944 | ||
| Type-I interferon signaling through ISGF3 complex is required for sustained Rip3 activation and necroptosis in macrophages. | Q34025307 | ||
| Regulated necrosis: the expanding network of non-apoptotic cell death pathways. | Q34039639 | ||
| Interferon-stimulated genes: a complex web of host defenses | Q34405609 | ||
| Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. | Q34413744 | ||
| The two faces of interferon-γ in cancer | Q35269015 | ||
| Caspase-8 scaffolding function and MLKL regulate NLRP3 inflammasome activation downstream of TLR3 | Q35781701 | ||
| The role of deoxyribonucleic acid in ribonucleic acid synthesis. III. The inhibition of the enzymatic synthesis of ribonucleic acid and deoxyribonucleic acid by actinomycin D and proflavin | Q36395687 | ||
| Interferome v2.0: an updated database of annotated interferon-regulated genes | Q36491580 | ||
| Sequential Engagement of Distinct MLKL Phosphatidylinositol-Binding Sites Executes Necroptosis | Q36626724 | ||
| Characterization of RIPK3-mediated phosphorylation of the activation loop of MLKL during necroptosis | Q36751262 | ||
| MLKL forms cation channels | Q36869946 | ||
| CYLD Proteolysis Protects Macrophages from TNF-Mediated Auto-necroptosis Induced by LPS and Licensed by Type I IFN. | Q37008848 | ||
| Interferon-induced RIP1/RIP3-mediated necrosis requires PKR and is licensed by FADD and caspases | Q37104059 | ||
| Cytokines in cancer immunotherapy | Q37148152 | ||
| IFN inducibility of major histocompatibility antigens in tumors | Q37341021 | ||
| The pseudokinase MLKL mediates programmed hepatocellular necrosis independently of RIPK3 during hepatitis | Q37395814 | ||
| Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. | Q37697383 | ||
| The IRF family transcription factors at the interface of innate and adaptive immune responses | Q38149074 | ||
| Antitumour actions of interferons: implications for cancer therapy | Q38748641 | ||
| MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. | Q38996643 | ||
| Combination of IAP antagonist and IFNγ activates novel caspase-10- and RIPK1-dependent cell death pathways. | Q39010178 | ||
| Type I interferons induce apoptosis by balancing cFLIP and caspase-8 independent of death ligands | Q39228077 | ||
| The host microRNA miR-301a blocks the IRF1-mediated neuronal innate immune response to Japanese encephalitis virus infection | Q40333366 | ||
| Interferon-gamma regulates inflammatory cell death by targeting necroptosis in experimental autoimmune arthritis | Q41581737 | ||
| Active MLKL triggers the NLRP3 inflammasome in a cell-intrinsic manner. | Q41851303 | ||
| MLKL Activation Triggers NLRP3-Mediated Processing and Release of IL-1β Independently of Gasdermin-D. | Q42320314 | ||
| The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells | Q42663433 | ||
| Involvement of the IRF-1 transcription factor in antiviral responses to interferons | Q44518832 | ||
| Smac mimetics and type II interferon synergistically induce necroptosis in various cancer cell lines | Q47783217 | ||
| MLKL, the Protein that Mediates Necroptosis, Also Regulates Endosomal Trafficking and Extracellular Vesicle Generation | Q47969532 | ||
| Linear ubiquitination of cytosolic Salmonella Typhimurium activates NF-κB and restricts bacterial proliferation | Q48178189 | ||
| Non-Hematopoietic MLKL Protects Against Salmonella Mucosal Infection by Enhancing Inflammasome Activation | Q49884899 | ||
| MLKL and FADD Are Critical for Suppressing Progressive Lymphoproliferative Disease and Activating the NLRP3 Inflammasome. | Q50493756 | ||
| Constitutive interferon signaling maintains critical threshold of MLKL expression to license necroptosis. | Q54108143 | ||
| Interferon gamma induces upregulation and activation of caspases 1, 3, and 8 to produce apoptosis in human erythroid progenitor cells | Q77419606 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 74-81 | |
| P577 | publication date | 2019-01-01 | |
| P1433 | published in | Neoplasia | Q2962042 |
| P1476 | title | Interferons Transcriptionally Up-Regulate MLKL Expression in Cancer Cells | |
| P478 | volume | 21 |
| Q91260101 | Current translational potential and underlying molecular mechanisms of necroptosis |
| Q90709088 | MLKL-dependent signaling regulates autophagic flux in a murine model of non-alcoholic fatty liver disease |
| Q98665172 | Myofiber necroptosis promotes muscle stem cell proliferation via releasing Tenascin-C during regeneration |
| Q65002198 | Programmed necrotic cell death of macrophages: Focus on pyroptosis, necroptosis, and parthanatos. |
| Q94562136 | Taking aim with IAP antagonists at triple-negative breast cancer: a moving target no more? |
Search more.